Literature DB >> 1193713

Type specificity of complement-requiring and immunoglobulin M neutralizing antibody in initial herpes simplex virus infections of humans.

N J Schmidt, B Forghani, E H Lennette.   

Abstract

Studies comparing the enhancing effect of guinea pig complement on homotypic and heterotypic neutralizing antibodies produced in initial herpes simplex virus (HSV) infections of humans indicated that antibodies to HSV type 1 and HSV type 2 were enhanced to about the same extent, and there was no signigicant difference in the degree to which complement enhanced homotypic and heterotypic HSV-neutralizing antibody. Homotypic and heterotypic immunoglobulin G neutralizing antibodies were enhanced by complement to as great, or greater, an extent as immunoglobulin M (IgM) HSV antibodies in the same sera. In patients with initial HSV type 1 infections, the IgM neutralizing antibody response was type specific. On the other hand, patients with initial HSV type 2 infections produced both homotypic and heterotypic IgM neutralizing antibody. An initial HSV type 2 infection in an individual previously infected with HSV type 1 elicited the production of IgM neutralizing antibody to both HSV type 1 and HSV type 2. However, patients with recurrent HSV type 1 infections failed to produce IgM antibody to either HSV type during reactivation of the virus.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1193713      PMCID: PMC415348          DOI: 10.1128/iai.12.4.728-732.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  Passive hemagglutinating antibodies in cerebrospinal fluids in herpesvirus hominis encephalitis. 1.

Authors:  A M Lerner; C B Lauter; D C Nolan; M J Shippey
Journal:  Proc Soc Exp Biol Med       Date:  1972-09

2.  Complement requirement of neutralizing antibodies appearing after primary and booster immunizations with herpes simplex virus.

Authors:  K Yoshino; T Morishima; Y Aoki
Journal:  Jpn J Microbiol       Date:  1971-01

3.  Immunological relationship between herpes simplex and varicella-zoster viruses demonstrated by complement-fixation, neutralization and fluorescent antibody tests.

Authors:  N J Schmidt; E H Lennette; R L Magoffin
Journal:  J Gen Virol       Date:  1969-04       Impact factor: 3.891

4.  Complement-requiring neutralizing antibodies in Herpesvirus hominis encephalitis.

Authors:  A M Lerner; E J Bailey; D C Nolan
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Heterogeneity in the properties of 7 S and 19S rabbit-neutralizing antibodies to herpes simplex virus.

Authors:  B Hampar; A L Notkins; M Mage; M A Keehn
Journal:  J Immunol       Date:  1968-03       Impact factor: 5.422

6.  Herpes simplex neutralizing antibody--quantitation of the complement-dependent fraction in different phases of adult human infection.

Authors:  H S Heineman
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

7.  Evaluation of the demonstration of complement-requiring neutralizing antibody as a means for early diagnosis of herpes virus infections.

Authors:  K Yoshino; S Taniguchi
Journal:  J Immunol       Date:  1966-02       Impact factor: 5.422

8.  Demonstration of rubella IgM antibody by indirect fluorescent antibody staining, sucrose density gradient centrifugation and mercaptoethanol reduction.

Authors:  B Forghani; N J Schmidt; E H Lennette
Journal:  Intervirology       Date:  1973       Impact factor: 1.763

9.  Specific IgG and IgM antibody responses in herpes-simplex-virus infections.

Authors:  J B Kurtz
Journal:  J Med Microbiol       Date:  1974-08       Impact factor: 2.472

10.  Indirect hemagglutinating antibody response to Herpesvirus hominis types 1 and 2 in immunized laboratory animals and in natural infections of man.

Authors:  A F Back; N J Schmidt
Journal:  Appl Microbiol       Date:  1974-09
View more
  9 in total

1.  Antibody assays for varicella-zoster virus: comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation.

Authors:  B Forghani; N J Schmidt; J Dennis
Journal:  J Clin Microbiol       Date:  1978-11       Impact factor: 5.948

2.  Neutralizing serum IgM antibodies in infections with Herpes simplex virus hominis.

Authors:  H W Doerr; G Gross; H Schmitz
Journal:  Med Microbiol Immunol       Date:  1976-12-01       Impact factor: 3.402

3.  Studies on the neutralizing antibody to herpes simplex virus. I. Effect of heterotypic antigenic stimulus on the type specificity of neutralizing antibody in rabbits.

Authors:  M Ohashi; Y Ozaki
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Type specificity and use of human sera for rapid typing of herpes simplex virus isolates by an indirect peroxidase-labeled antibody technique: a comparison with three other methods.

Authors:  G Gerna; J Ditmore; R W Chambers
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

5.  Complement-fixing reactivity of Varicella-Zoster virus subunit antigens with sera from homotypic infections and heterotypic Herpes simplex virus infections.

Authors:  N J Schmidt; J Dennis; E H Lennette
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

6.  Determination of specific IGA antibodies to varicella zoster virus by immunoperoxidase assay.

Authors:  H Haikin; I Sarov
Journal:  J Clin Pathol       Date:  1982-06       Impact factor: 3.411

7.  Typing of herpes simplex virus with type-specific human immunoglobulin M in an indirect immunofluorescence assay.

Authors:  S L Spruance; C A Golden; E R Kern; M E Katz; F Chow
Journal:  J Clin Microbiol       Date:  1982-02       Impact factor: 5.948

8.  Relationship of antibody to outcome in neonatal herpes simplex virus infections.

Authors:  A S Yeager; A M Arvin; L J Urbani; J A Kemp
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.

Authors:  Tamara P Blevins; Michelle C Mitchell; Maria Korom; Hong Wang; Yinyi Yu; Lynda A Morrison; Robert B Belshe
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.